Sign in

ANL on Nasdaq

Adlai Nortye Group Ltd.

Adlai Nortye Group Ltd. is an American pharmaceutical preparations company, incorporated in Delaware.1 Its shares trade on Nasdaq under the symbol ANL.1

Price unavailable

Last updated Oct 21, 2026.

Overview

-$51.9MNet income, fiscal 20242

Compare with PROCYON CORP, InMed Pharmaceuticals Inc. or Ensysce Biosciences, or pick any stock.

  • TickerANL on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersDE1
  • Incorporated inDE3
  • Business address77 Robinson Road, #20-01, Robinson 77, Singapore, 0688963
  • Filer categoryNon-accelerated filer, Emerging growth company3

See how the biggest companies compare on our leaderboards

CStone Pharmaceuticals. Before that, Dr. Tse held leadership positions in multinational companies, including MSD and Daiichi-Sankyo.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-1451.0%Operating margin2
-2184.6%Net margin2
-145.5%Return on equity2
-$56.9MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development98¢$58.2M
  • Interest1¢$791.0K
  • Income tax1¢$643.0K

Out of $5.0M in revenue.25 The company lost money this year.

Financial statements

Revenue52$5.0M in 2023−89% since 2021
0$20.0M$40.0M$60.0M2021: $45.7M$45.7M20212023: $5.0M$5.0M2023−89%
Operating income52-$72.6M in 2023+739% since 2021
-$80.0M-$60.0M-$40.0M-$20.0M02021: -$8.6M-$8.6M20212022: -$67.3M-$67.3M2022+678%2023: -$72.6M-$72.6M2023+8%
Net income52-$109.2M in 2023+93% since 2021
-$150.0M-$100.0M-$50.0M02021: -$56.7M-$56.7M20212022: -$58.8M-$58.8M2022+4%2023: -$109.2M-$109.2M2023+86%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-12-312024-12-312023-12-31
REVENUE$5.0M
Other operating income, net$396.0K$1.9M$890.0K
General and administrative expense-$8.3M-$10.0M-$15.3M
Research and development expenses-$32.8M-$44.9M-$58.2M
Total operating loss-$35.7M-$52.9M-$72.6M
Other income and gains$1.5M$3.0M$3.3M
Other (expenses)/income$228.0K-$42.0K-$80.0K
Investment income$1.0K$62.0K
Share of loss of investments accounted for using the equity method-$3.0K-$4.0K
Fair value loss on financial liabilities at FVTPL-$39.2M
Finance costs-$1.5M-$1.9M-$791.0K
LOSS BEFORE TAX-$35.5M-$51.9M-$109.2M
LOSS FOR THE YEAR-$35.5M-$51.9M-$109.2M
Ordinary Equity Holders of the Parent-$35.5M-$51.9M-$109.2M
Exchange differences on translation of the financial statements of subsidiaries$189.0K-$294.0K-$82.0K
Other comprehensive (loss)/income for the year, net of tax$189.0K-$294.0K-$82.0K
TOTAL COMPREHENSIVE LOSS FOR THE YEAR-$35.3M-$52.2M-$109.3M
Ordinary Equity Holders of the Parent-$35.3M-$52.2M-$109.3M
Basic loss for the year (in Dollars per share)-$0.37-$0.54-$2.52
Diluted loss for the year (in Dollars per share)-$0.37-$0.54-$2.52
Weighted average common shares outstanding, basic (in Shares)95.9M shares95.8M shares43.3M shares
Weighted average common shares outstanding, diluted (in Shares)95.9M shares95.8M shares43.3M shares

Compare Adlai Nortye Group Ltd. with another company

Corporate structure

Adlai Nortye Group Ltd. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Adlai Nortye Group Ltd.

  • Adlai Nortye Group Ltd. DE

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Adlai Nortye Group Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$1.7M2 Dec 31, 2024$2.6M2 Dec 31, 2023−34.1%
Operating-lease assets (leased space)$962.0K2 Dec 31, 2024$1.2M2 Dec 31, 2023−16.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$60.9M2 Dec 31, 2024$91.5M2 Dec 31, 2023−33.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$40.0K2 Dec 31, 2024$63.0K2 Dec 31, 2023−36.5%

Leadership

Who has led Adlai Nortye Group Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Yang Lu2026–now

President

  1. Archie Tse2026–now

Chief financial officer

  1. Xiaofeng Ye2026–now
Board members and other officers (5)

Former names

  • Adlai Nortye Ltd.Dec 21, 2022 to Aug 19, 20263

Timeline

  1. May 21, 2026New chief executive Yang Lu becomes CEO7

Calendar

Drug trials and FDA: recently

  1. Nov 2, 2025Phase 3 trial completed Phase 3 trial of Buparlisib & Paclitaxel in Head and Neck Cancer: primary completion Nov 2, 2025, no results posted yet (ClinicalTrials.gov NCT04338399).14

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

113 filings to the SEC since October 2021: 5 annual reports, 15 insider forms, 15 large holders, 78 other. The latest 20:

  1. Oct 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  2. Oct 1, 20264 PRIMARY DOCUMENT EDGAR
  3. Sep 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  4. Sep 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  5. Sep 24, 20264 PRIMARY DOCUMENT EDGAR
  6. Sep 18, 2026144 EDGAR
  7. Sep 15, 2026EFFECT EDGAR
  8. Sep 11, 2026S-8 POS REGISTRATION STATEMENT EDGAR
  9. Sep 11, 2026S-8 POS REGISTRATION STATEMENT EDGAR
  10. Sep 11, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3 EDGAR
  11. Sep 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  12. Aug 26, 20264 PRIMARY DOCUMENT EDGAR
  13. Aug 26, 20266-K CURRENT REPORT EDGAR
  14. Aug 19, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  15. Aug 14, 2026SCHEDULE 13G/A EDGAR
  16. Aug 14, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  17. Aug 14, 2026SCHEDULE 13G/A EDGAR
  18. Aug 4, 20263 PRIMARY DOCUMENT EDGAR
  19. Aug 3, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  20. Jul 20, 2026424B7 PROSPECTUS SUPPLEMENT EDGAR

The 113 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 0 buys and 4 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 22, 2026Ji PingDirectorSale5,000$16.63$83.2KForm 4
Aug 26, 2026Ye XiaofengCFOSale5,667$14.25$80.8KForm 4
Aug 24, 2026Ye XiaofengCFOSale6,000$13.98$83.9KForm 4
May 13, 2026LU YANGCEOSale10$13.18$132Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 42. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Cormorant Asset Management, LP3,978,229$45.7M2.3%+1,080,372
Venrock Adviser, LLC3,212,731$36.9M1.1%No change
Balyasny Asset Management L.P.3,061,668$35.2M0.1%+2,183,822
Point72 Asset Management, L.P.2,140,664$24.6M0.0%New
Mpm Bioimpact LLC1,936,291$22.3M1.4%New
Perceptive Advisors LLC1,793,190$20.6M0.3%New
Casdin Capital, LLC1,250,000$14.4M0.7%+711,539
ADAR1 Capital Management, LLC1,017,805$11.7M0.6%+899,896
Octagon Capital Advisors LP934,716$10.7M1.0%New
Millennium Management LLC807,832$9.3M0.0%+126,057
Braidwell LP795,214$9.1M0.4%New
Squadron Capital Management LLC764,876$8.8M3.0%−500,355
Eventide Asset Management, LLC718,747$8.3M0.1%New
Superstring Capital Management LP552,501$6.4M4.0%+137,649
Adage Capital Partners Gp, L.l.c.538,461$6.2M0.0%No change
Woodline Partners LP455,733$5.2M0.0%+246,474
Soleus Capital Management, L.P.405,523$4.7M0.2%New
Freestone Grove Partners LP397,446$4.6M0.0%New
Boone Capital Management LLC258,390$3.0M0.7%New
DAFNA Capital Management LLC239,553$2.8M0.5%New
Kalehua Capital Management LLC226,415$2.6M0.8%New
Affinity Asset Advisors, LLC153,847$1.8M0.1%−10,901
Seven Fleet Capital Management LP113,207$1.3M0.2%New
DV Trading LLC113,207$1.3M0.1%New
Renaissance Technologies LLC94,100$1.1M0.0%+28,100

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Adlai Nortye Group Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAdlai Nortye Group Ltd.1
  • CIK0001944552
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company4
  • Incorporated inCayman Islands4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address77 Robinson Road, #20-01, Robinson 77, Singapore, 068896, Singapore1
  • Phone848-230-74301
  • Shares outstanding103,010,803 Classa Ordinary Shares shares; 16,990,000 Classb Ordinary Shares shares as of Dec 31, 20254
  • AuditorBDO China Shu Lun Pan Certified Public Accountants LLP, Shanghai, The People’s Republic of China PCAOB ID 1818; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceDec 21, 20221
  • Filings113 in all: 6-K (26), CORRESP (10), UPLOAD (10), 3 (8), SC 13G (6), 4 (5), DRSLTR (5), SCHEDULE 13G (5)1
    All 27 form types

    DRS/A (4), F-1/A (4), SCHEDULE 13G/A (4), 20-F (3), EFFECT (3), 20-F/A (2), 3/A (2), 8-A12B (2), F-3/A (2), S-8 (2), S-8 POS (2), 144 (1), 424B4 (1), 424B7 (1), CERT (1), DRS (1), F-1 (1), F-3 (1), POS AM (1)

  • Latest filingsAnnual report (20-F) Apr 10, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing three Class A Ordinary Shares, par value $0.0001 per shareANLNasdaq

From the cover page of the 20-F filed Apr 10, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24